Comparison · NCT05361655-deaths
Palbociclib + Aromatase Inhibitor vs Aromatase Inhibitor: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Palbociclib + Aromatase Inhibitor vs Aromatase Inhibitor: deaths from any cause. Trial comparisons, record NCT05361655-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05361655-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.317 | 0.293 | 0.343 | wilson | |
| Risk in group 2 | 0.471 | 0.446 | 0.495 | wilson | |
| Risk difference, group 1 minus group 2 | -0.153 | -0.188 | -0.118 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.674 | 0.613 | 0.741 | log | |
| Odds ratio, group 1 over group 2 | 0.523 | 0.449 | 0.609 | log | |
| Number needed to treat, for one fewer death from any cause on Palbociclib + Aromatase Inhibitor than on Aromatase Inhibitor | 6.52 | 5.31 | 8.48 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Palbociclib + Aromatase Inhibitor | Participants with HR+/HER2- MBC who initiated first line treatment with palbociclib + aromatase inhibitor between 03 Feb 2015 to 31 Mar 2020 were included and observed. | 420 | 1,324 | EG000 |
| Group 2 | Aromatase Inhibitor | Participants with HR+/HER2- MBC who initiated first line treatment with aromatase inhibitor alone between 03 Feb 2015 to March 2020 were included and observed. | 736 | 1,564 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor
- NCT number
- NCT05361655
- Phases
- Conditions
- Metastatic Breast Cancer
- Interventions
- Palbociclib + an aromatase inhibitor, Aromatase inhibitor
- Lead sponsor
- Pfizer
- Results first posted
- 2024-06-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05361655?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05361655-deaths